<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890188</url>
  </required_header>
  <id_info>
    <org_study_id>HR-97-035</org_study_id>
    <nct_id>NCT00890188</nct_id>
  </id_info>
  <brief_title>Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer</brief_title>
  <acronym>UFUR</acronym>
  <official_title>The Feasibility of Combing THALIDOMIDE and UFUR in the Treatment of Advanced Colorectal Cancer After Oxaliplatin-Contained Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer is a major health problem in Western society contributing to a high&#xD;
      mortality rate. Treatment options for the majority of patients with metastases are limited to&#xD;
      cytotoxic chemotherapies. The first line chemotherapy containing with oxaliplatin is&#xD;
      recommend by guideline. The use of antiangiogenic agents, either alone or in combination with&#xD;
      other therapies may provide an alternative treatment modality in the management of these&#xD;
      patients. Metronomic chemotherapy refers to the close, regular administration of a&#xD;
      chemotherapeutic drug, over prolonged periods. The advantages of metronomic chemotherapy&#xD;
      include reducing acute toxicities and sometimes surprisingly good activity against drug&#xD;
      resistant tumors via antiangiogenic effect.&#xD;
&#xD;
      Thalidomide is an agent, which has shown potential in the treatment of hematological and&#xD;
      solid tissue malignancies such as multiple myeloma via antiangiogenic mechanism.&#xD;
      Tegafur/uracil (UFUR) is one of the effective chemotherapeutics reported to be an effective&#xD;
      antiangiogenic agent in an animal model of metastatic colorectal cancers (CRCs).&#xD;
&#xD;
      In the present study, the investigators will try to use low dose metronomic schedule of&#xD;
      thalidomide with tegafur/uracil regimen to see the anti tumor efficacy in recurrent and&#xD;
      metastasis colorectal cancer patients after oxaliplatin-contained chemotherapy.&#xD;
&#xD;
      The primary endpoints are overall response rate and clinical benefit and the secondary&#xD;
      endpoint were to determine the progression free survival, and duration of objective response,&#xD;
      the overall survival (OS) and to assess the safety profile. This is a prospective phase II&#xD;
      study. After having checked all eligibility criteria, patients will be treated with&#xD;
      Tegafur/Uracil (TU) regimen. About 34 patients will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response(CR+PR) and Clinical benefit (CR+PR+SD)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the progression free survival, overall survival (OS)and assess the safety profile</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>THALIDOMIDE and UFUR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THALIDOMIDE and UFUR</intervention_name>
    <description>T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle</description>
    <arm_group_label>THALIDOMIDE and UFUR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal carcinoma&#xD;
&#xD;
          -  Patients must have received at least one oxaliplatin-contained chemotherapy before the&#xD;
             study and did not want to receive or tolerate irinotecan- contained chemotherapy&#xD;
&#xD;
          -  Presence of at least one measurable disease which is defined as lesion that can be&#xD;
             measured in at least 1 dimension as 20 mm with conventional CT or 10 mm with spiral CT&#xD;
             scan&#xD;
&#xD;
          -  Age ≥ 18 year, ECOG performance status 0, 1, 2, 3&#xD;
&#xD;
          -  White blood cell (WBC) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3,&#xD;
             platelets ≥ 100,000/mm3 and hemoglobin ≥ 8 mg / dl&#xD;
&#xD;
          -  Serum creatinine level 2.0 mg/dL or lower&#xD;
&#xD;
          -  Serum bilirubin less than 1.5 times the upper limit of normal range (ULN)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 2.5 times&#xD;
             the ULN if no demonstrable liver metastases or less than 5 times the ULN in the&#xD;
             presence of liver metastases&#xD;
&#xD;
          -  Require to wait 28 days before entry onto the study after being treated with any&#xD;
             immunotherapy, or biologic systemic (including any target therapy)&#xD;
&#xD;
          -  Written informed consent to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of CNS metastasis&#xD;
&#xD;
          -  Other malignancy with the exception of curative treated non-melanoma skin cancer or&#xD;
             cervical carcinoma in situ within 5 years prior to the entry of study&#xD;
&#xD;
          -  Less than 4 weeks since previous treatment&#xD;
&#xD;
          -  Concomitant illness that might be aggregated by chemotherapy. For examples, active,&#xD;
             non-controlled infection or other active, non-controlled disease such as congestive&#xD;
             heart failure, angina pectoris, respiratory insufficiency, arrhythmia. It depends on&#xD;
             investigation's decision.&#xD;
&#xD;
          -  Women of child-bearing potential without using a reliable and appropriate&#xD;
             contraceptive method during study period&#xD;
&#xD;
          -  Pre existent sensory or motor neurotoxicity &gt; grade 2 according to National Cancer&#xD;
             Institute (NCI) Common Toxicity Criteria (CTC) (disabling paresthesia and/or&#xD;
             significant motor loss)&#xD;
&#xD;
          -  Patients who are receiving other concomitant chemotherapy, radiotherapy or any other&#xD;
             investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Chan Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital, Clinical Trial Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Chan Lin, MD</last_name>
    <phone>+886-062353535</phone>
    <phone_ext>4559</phone_ext>
    <email>pengchanlin@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Chan Lin, MD</last_name>
      <phone>+886-06-2353535</phone>
      <phone_ext>4559</phone_ext>
      <email>pengchanlin@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Peng Chan Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>May 5, 2009</last_update_submitted>
  <last_update_submitted_qc>May 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Peng-Chan Lin/Doctor</name_title>
    <organization>National Cheng-Kung University Hospital</organization>
  </responsible_party>
  <keyword>THALIDOMIDE</keyword>
  <keyword>UFUR</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

